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A b s t r a c t
To assess whether the potentially high-risk (HR) 
human papillomavirus (HPV)-related up-regulation 
of 14-3-3  (stratifin) has implications in the 
outcome of HPV infections or cervical intraepithelial 
neoplasia (CIN) lesions, cervical biopsy specimens 
from 225 women in the Latin American Screening 
Study were analyzed for 14-3-3  expression using 
immunohistochemical analysis. We assessed its 
associations with CIN grade and HR HPV at baseline 
and value in predicting outcomes of HR-HPV infections 
and the development of incident CIN 1+ and CIN 2+.
Expression of 14-3-3  increased in parallel with 
the lesion grade. Up-regulation was also significantly 
related to HR-HPV detection (P = .004; odds ratio, 
2.71; 95% confidence interval, 1.37-5.35) and showed 
a linear relationship to HR-HPV loads (P = .003). 
14-3-3  expression was of no value in predicting the 
outcomes (incident, persistent, clearance) of HR-HPV 
infections or incident CIN 1+ and CIN 2+.
14-3-3  is not inactivated in cervical carcinoma 
and CIN but is up-regulated on transition from CIN 2 
to CIN 3. Its normal functions in controlling G1/S and 
G2/M checkpoints are being bypassed by HR HPV.
Practically all cervical carcinomas (CCs) are caused 
by high-risk human papillomavirus (HR-HPV) infections, 
whereas the low-risk (LR) HPV types are rarely found in 
CC or its precursor (cervical intraepithelial neoplasia [CIN]) 
lesions.1-6 This divergent oncogenic potential of LR HPV 
and HR HPV is mainly attributable to the differences of the 
2 major viral oncoproteins (E6 and E7) to interact with the 
key regulatory cellular proteins, p53 and pRb.1,4,7-9 While 
E6 of HR HPV (but not LR HPV) initiates degradation of 
the p53 tumor suppressor protein, HPV E7 of HR HPV (but 
not LR HPV) binds to pRb, resulting in G1/S transition of 
the cell.1,4,7-11 In addition to this G1/S checkpoint, E6 and 
E7 (together with several cellular proteins) also control the 
G2/M checkpoint.7-9,11 One of the cellular G2/M checkpoint–
controlling proteins is 14-3-3 , also known as stratifin.12
The 14-3-3  gene was originally characterized from 
normal mammary epithelium as a human mammary epithelial 
marker (HME1), and its expression was markedly reduced 
in breast cancer cells.13 14-3-3 proteins represent a family 
of highly homologous proteins and have been described in 
all eukaryotic organisms.12 The mammalian 14-3-3 isoforms 
, , , , , , and  are encoded by 7 individual genes.12,14
14-3-3  expression is mediated by p53 and p21, following 
various types of DNA damage, and 14-3-3  has an important 
role in preventing mitotic catastrophe after DNA damage, 
sequestering the cyclin-B1 and cyclin-dependent kinase 1 
(CDK1) complexes from the nucleus to the cytoplasm, result-
ing in G2/M cell cycle arrest.15,16 Furthermore, 14-3-3  binds 
to CDK1, CDK2, CDK4, and their related complexes and 
inhibits the cells from entering the cell cycle.17,18
In addition to this G2/M checkpoint control,12-18 14-3-3 
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including signal transduction, apoptosis, transcriptional 
regulation, and coordination of cell adhesion and motil-
ity.19-21 Thus, 14-3-3 proteins in human carcinogenesis 
have attracted considerable interest.14,22 Despite the alleged 
tumor suppressor activity of 14-3-3 , this gene has been 
shown to be inactivated in most human malignancies.14,22-24
It is interesting that this inactivation is not the result of 
mutation or gene deletion but is due to epigenetic inactiva-
tion by promoter methylation.14,22-24
In contrast with most other malignant tumors,14,22-24
CC and CIN lesions seem to continue normal expression of 
14-3-3 , which shows even up-regulation as compared with 
the normal epithelium.25 The reasons for this paradoxical 
behavior of 14-3-3  in CC and CIN are not understood, 
but interactions with HR HPV are implicated. Until now, 
however, expression of 14-3-3  in CC and CIN lesions has 
been analyzed in 1 study only.25 While strong and diffuse 
immunoreactivity for 14-3-3  was uniformly observed in 
all CIN and squamous cell carcinoma lesions, some (HPV–) 
adenosquamous carcinomas and adenocarcinomas did not 
express 14-3-3 . Concomitant inactivation of 14-3-3
and p16 was never observed, suggesting that inactivation 
of 14-3-3  or p16 might have an effect equivalent to the 
expression of HR HPV E6 and E7 oncoproteins.
To further delineate the role of 14-3-3  in HR HPV–
associated cervical carcinogenesis, we analyzed a series of 
cervical biopsy specimens derived from 225 women includ-
ed in the Latin American Screening (LAMS) Study cohort 
(n = 12,114) in Brazil and Argentina.26-29 The study aimed 
to assess whether the expression of 14-3-3  is associated 
with the grade of CIN and HR HPV type at baseline and 
predict the outcome of these HR-HPV infections or devel-
opment of incident CIN 1+ and CIN 2+ during prospective 
follow-up of the women.26,27
Materials and Methods
General Study Design
The ongoing LAMS Study is a multicenter screening 
trial targeting female populations at different risk for CC 
in 2 Latin American countries, Brazil and Argentina.26 At 
their baseline visit, a total of 12,114 consecutive women 
attending the 4 partner clinics, Campinas, Brazil; Sao Paulo, 
Brazil; Porto Alegre, Brazil; and Buenos Aires, Argentina, 
were screened for HPV and CIN using 8 different diagnostic 
tools, as detailed before.26-29 Women testing positive with 
any of these diagnostic tests were examined by colposcopy 
(and biopsied) at their second visit. In addition, a 5% ran-
dom sample of Papanicolaou (Pap) smear–negative women 
were recalled for a new Pap test at 12 months, as were 
20% of women testing negative with the Hybrid Capture II 
(HC2; Digene, Gaithersburg, MD) assay, to assess the rates 
of incident Pap smear abnormalities and HPV infections, 
respectively.26,27 The women with biopsy-confirmed low-
grade CIN comprise the prospective cohort (n = 1,011) and 
were followed up for a minimum of 24 months. All high-
grade lesions were promptly treated and followed up for the 
same period, using repeated Pap test, colposcopy, and HC2 
assay at 12-month intervals.26-29 For the present analysis of 
stratifin, baseline biopsy samples taken from 225 of these 
women were available.
Prospective Follow-up
According to the aforementioned criteria, women were 
allocated to the prospective cohort and scheduled to be 
monitored in the clinic at 6-month intervals for a minimum 
of 24 months. A total of 1,011 women completed at least 
1 follow-up visit including examination by Pap smear, 
visual inspection with acetic acid and with Lugol iodine, 
colposcopy, and biopsy, whenever abnormalities were 
detected.27-29 The mean follow-up time as of this writing 
was 21.7 months (SD, 8.09 months; median, 24.2 months; 
range, 1-54 months).
Outcomes and End Points of Cervical Lesions and 
HR-HPV Infections
In the present study, biopsies from 225 women included 
in this subcohort of 1,011 women were analyzed for the sur-
rogate end points of progressive disease: progression to CIN 
1+ and progression to CIN 2+, and for outcomes of their 
HR-HPV infections, including incident infections, virus 
persistence, and HPV clearance. Progression to CIN 1+ was 
based on detection, in baseline biopsy-negative women, of 
a biopsy-confirmed CIN 1+ lesion in any of the consecutive 
visits during the follow-up period. Progression to CIN 2+ 
was defined as any case in which biopsy-confirmed progres-
sion from a baseline negative, flat HPV lesion with no CIN, 
or CIN 1 biopsy was established in the subsequent follow-
up-visits, as recently detailed.30 Times to progression to CIN 
1+ and CIN 2+ were calculated from the baseline visit to the 
respective follow-up visit when the progression event was 
first detected. Progression rates were calculated by dividing 
the numbers of progressed cases by woman-months at risk 
(WMR) and expressed per 1,000 WMR. 
Three outcomes of HR-HPV infections were recorded: 
incident, persistence, and clearance. An incident HR-HPV 
infection involved the appearance of a positive HC2 test (at 
1pg/mL relative light units/cutoff ratio) among baseline HR 
HPV–negative women at any of the follow-up visits. HR 
HPV was considered cleared if the HC2 assay was negative 
at the last follow-up visit. Persistent HR-HPV infections 
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were HR HPV–positive and the infection was not cleared at 
the last follow-up visit. Times to the 3 outcomes were also 
calculated and expressed as cases per 1,000 WMR.
LAMS Study Methods
Because they are detailed in a series of recent reports,26-30
the methods used in the LAMS Study are described here 
only as pertinent to elaborating the data necessary for the 
present analysis.
Epidemiologic Questionnaire
All women who gave their consent to participate (n = 
12,114) completed a detailed inquiry concerning the risk 
factors for HPV, CIN, and CC. This structured question-
naire contained questions exploring reproductive history, 
sexual history, current sexual practices, sexual hygiene, 
medical history, smoking habits, and contraception.26,27
Pap Smears
In the LAMS Study, we compared the performance 
of 3 methods of cervical cytology: conventional Pap 
and 2 liquid-based cytology techniques (DNA-Citoliq, 
Digene Brazil, Sao Paulo; and SurePath, TriPath, Durham, 
NC).26,27 In the present analysis, only the results of the 
conventional Pap test were used.
Directed Punch Biopsy
Directed punch biopsy and cone biopsy specimens 
were fixed in formalin, embedded in paraffin, and pro-
cessed into 5- m-thick H&E-stained sections for light 
microscopy, following the routine procedures. All biopsy 
specimens were examined within the daily routine in the 
pathology departments of the partner clinics in both stud-
ies and diagnosed using the commonly agreed-on CIN 
nomenclature. The pathologists were also asked to report 
the HPV-suggestive morphologic changes in flat lesions 
with no CIN (ie, HPV NCIN [flat condyloma]).26-29 The 
slides from two of the centers (Campinas and Sao Paulo) 
were subjected to reexamination by a panel of pathologists 
from the European Community partners (M.E. and K.S.). 
The consensus diagnosis of the panel was considered the 
final diagnosis.
Detection of HPV DNA by the HC2 Assay
Primary HPV testing was done by using the HC2 
assay, using cervical swabs (collected by a physician) 
and self-sampling devices (tampons), as described previ-
ously.26,29 The HC2 assay (n = 4,694 tests) was performed 
using the automated HC2 test system according to the 
manufacturer’s protocol. The samples were analyzed only 
for the presence of HR HPV types 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, and 68. The usual limit of 1 pg/mL of 
HPV-16 DNA was used as the positive control (cutoff), ie, 
samples were classified as HR HPV–positive with a rela-
tive light units/cutoff ratio of 1.0 pg/mL or more.
Immunohistochemical Detection of Stratifin (14-3-3 )
A total of 225 slides from the same number of women 
were available for immunohistochemical analysis of stratifin. 
In brief, 4- m-thick sections were cut on ChemMate Capillary 
Gap Microscope slides (DAKO, Glostrup, Denmark), kept 
overnight at 55°C, deparaffinized in xylene, and rehydrated in 
graded alcohol. Before immunohistochemical analysis, strati-
fin antigen retrieval was done by heating the tissue sections 
in a buffer of 10 mmol/L tris(hydroxymethyl)aminomethane 
(Tris) and 1 mmol/L EDTA (pH 9.0) with a microwave oven 
(600 W) for 10 minutes. Immunohistochemical staining for 
stratifin was performed with the DAKO TechMate 500 Plus 
Autostainer using monoclonal 14-3-3  antibody (ab14123; 
Abcam, Cambridge, MA) diluted 1:75 and the reagents from 
the DAKO REAL-kit (DAKO). The sections were washed 
with distilled water and Tris-buffered saline. Then, the sec-
tions were stained with the primary antibody and the second-
ary biotinylated antibody (antimouse IgG) for 30 minutes. 
Endogenous peroxidase activity was blocked by using 5% 
hydrogen peroxide 3 times for 2 minutes, 30 seconds each. 
This was followed by incubation with streptavidin peroxidase 
for 30 minutes. The counterstaining was performed with hema-
toxylin for 1 minute, and the immunoperoxidase reaction was 
developed using 3,3'-diaminobenzidine 3 times for 5 minutes 
each. Finally, the sections were washed with distilled water and 
mounted with Aquamount (BDH Laboratory Supplies, Poole,
England). Negative control samples were similarly processed 
by omitting the primary antibody, and biopsy specimens from 
breast cancer were used as positive control samples.
Evaluation of Immunohistochemical Staining for Stratifin 
(14-3-3 )
In normal and metaplastic squamous epithelium, expres-
sion of stratifin was invariably present, being predominantly 
cytoplasmic and confined to the cells in the lowermost lay-
ers of the epithelium ❚Image 1❚. In CIN lesions and CC, 
cytoplasmic and nuclear stratifin expression was markedly 
increased, almost in parallel with the increasing grade of the 
lesion ❚Image 2❚, ❚Image 3❚, and ❚Image 4❚. In original grad-
ing of the stratifin staining, a semiquantitative scoring of 
4 categories was used: 0, no expression; 1, weak staining 
(equivalent to normal squamous epithelium); 2, moderately 
increased staining (intermediate cells stained); and 3, strongly 
increased staining (all layers diffusely positive for intense 
stratifin staining). In statistical analysis, the staining results 
were also treated as dichotomous variables (negative-weak vs 
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❚Image 1❚ Normal cervical epithelium undergoing physiologic 
squamous cell metaplasia. Stratifin expression is equivalent 
to that in the normal squamous epithelium. Stratifin 
expression is focal, predominantly cytoplasmic, and confined 
to the cells in the lower (and scattered in the intermediate) 
layers of the metaplastic epithelium (immunohistochemical 
analysis for stratifin, ×50).
❚Image 2❚ A low-grade cervical intraepithelial neoplasia-1 
lesion with characteristic features of human papillomavirus 
infection (koilocytes), from intermediate layers upwards. 
As compared with the metaplastic epithelium, cytoplasmic 
and nuclear expression of stratifin is increased in intensity, 
and positive staining is also present at higher levels of the 
epithelium. Yet, lacking the expression in the uppermost 
layers makes a major difference to high-grade lesions 
(immunohistochemical analysis for stratifin, ×100).
❚Image 3❚ A high-grade cervical intraepithelial neoplasia-3 
lesion penetrating into the underlying glandular openings. 
Stratifin-positive cells are found throughout the full thickness 
of the epithelium, indicating marked up-regulation. The 
staining intensity shows some variability, with some cells 
showing intense cytoplasmic and/or nuclear expression, 
while in the rest of the cells, stratifin expression is less 
intense (immunohistochemical analysis for stratifin, ×100).
❚Image 4❚ An invasive squamous cell carcinoma with intense 
expression of stratifin. Positive immunostaining is detected 
in practically all cancer cells, being an indicator of a marked 
overexpression of stratifin, even more diffuse than in the 
cervical intraepithelial neoplasia-3 lesion shown in Image 3 
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Statistical Methods
Statistical analyses were performed using the SPSS for 
Windows, version 16.0.2.1 (SPSS, Chicago, IL) and Stata/
SE 10.1 (Stata, College Station, TX) software packages. 
Frequency tables for categorical variables were analyzed by 
using the 2 test, with the likelihood ratio or Fisher exact 
test to assess the significance. Differences in the means of 
continuous variables were analyzed using nonparametric tests 
(Mann-Whitney) or analysis of variance. Performance indica-
tors (sensitivity, specificity, positive predictive value, negative 
predictive value, and their 95% confidence intervals [CIs]) for 
14-3-3  as a predictor of baseline high-grade CIN or HR HPV 
and the longitudinal predictive values for the 3 viral outcomes 
and incident CIN 1+ and CIN 2+ were calculated by using 
Stata/SE software and the algorithm introduced by Seed and 
Tobias,31 which also calculates the area under the receiver 
operating characteristic curve (AUC). In all tests, values of P
of less than .05 were considered statistically significant.
Results
Expression of 14-3-3  (stratifin) in cervical biopsy 
specimens as related to lesion grade is summarized in ❚Table
1❚. There was a significant linear trend of increasing up-
regulation of 14-3-3  (P = .0001) in parallel with increas-
ing grade of CIN. When dichotomized (negative-weak vs 
moderate-strong), up-regulated 14-3-3  expression predicted 
CIN 3+ with an odds ratio (OR) of 3.39 (95% CI, 1.25-9.14; 
P = .007) and CIN 2+ with an OR of 2.70 (95% CI, 1.27-5.76; 
P = .006).
❚Table 2❚ depicts the association of 14-3-3  expression 
with HR-HPV detection and semiquantitative viral load 
detected with the HC2 assay. Stratifin was clearly up-regulat-
ed more often in HR-HPV+ lesions than in those remaining 
HC2– (P = .008). Dichotomized expression was associ-
ated with HR-HPV detection with an OR of 2.71 (95% CI, 
1.37-5.35; P = .004). The log-transformed semiquantitative 
HR-HPV viral loads were also directly related to up-regula-
tion of 14-3-3  (P = .003). When the performance indicators 
were calculated, 14-3-3  was not a particularly good predictor 
of HR HPV, with an AUC of 0.608 (95% CI, 0.533-0.683).
Expression of 14-3-3  in the baseline biopsy specimens 
was related to outcome of the HPV infection ❚Table 3❚.
Up-regulation of 14-3-3  was a 100% sensitive marker in 
predicting incident HR HPV (AUC, 0.718) but was slightly 
less sensitive in predicting persistent HR-HPV infection or 
virus clearance using the longitudinal performance indicators. 
As to the time to clearance and time to incident HR HPV 
❚Table 1❚
Expression of Stratifin (14-3-3 ) as Related to Lesion Grade*
Stratifin Expression  
Lesion Grade Negative-Normal Expression Moderate Up-Regulation Strong Up-Regulation
Normal or HPV-NCIN (n = 94) 34 (36) 29 (31) 31 (33)
CIN 1 (n = 64) 23 (36) 23 (36) 18 (28)
CIN 2 (n = 21) 5 (24) 6 (29) 10 (48)
CIN 3 (n = 36) 5 (14) 5 (14) 26 (72)
SCC (n = 1) 0 (0) 0 (0) 1 (100)
CIN, cervical intraepithelial neoplasia; HPV-NCIN, flat HPV lesion with no CIN; SCC, squamous cell carcinoma.
* Data are given as number (percentage). P = .002 (Fisher exact test); P = .0001 for linear trend.
❚Table 2❚
Expression of Stratifin as Related to Detection of HR-HPV With the Hybrid Capture II Assay and Its Viral Load*
Stratifin Expression  
 Negative-Normal Expression Moderate Up-Regulation Strong Up-Regulation
High-risk HPV result†   
   HPV+ (n = 111) 25 (22.5) 34 (30.6) 52 (46.8)
   HPV– (n = 59) 26 (44) 17 (29) 16 (27)
Viral load‡ 1.30 (0.38-2.22) (n = 51) 2.85 (1.89-3.81) (n = 51) 3.32 (2.58-4.07) (n = 68)
CI, confidence interval; HPV, human papillomavirus.
* Performance indicators of dichotomous (moderate to strong vs negative to weak [normal]) stratifin are as follows: sensitivity, 77.5% (95% CI, 68.6-84.9); specificity, 
44.1% (95% CI, 31.2-57.6); positive predictive value, 72.3% (95% CI, 63.3-80.1); negative predictive value, 51.0% (95% CI, 36.6-65.2); area under the receiver operating 
characteristic curve, 0.608 (95% CI, 0.533-0.683).
† Data are given as number (percentage). P = .008 ( 2, log rank); P = .002 for linear trend.
‡ Data are given as mean (± 95% confidence interval). Semiquantitative viral load determined by the relative light units/cutoff ratio in the Hybrid Capture II assay, 
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(not calculable), there were no differences related to 14-3-3
expression. All these calculations are hampered by the small 
number of events.
❚Table 4❚ gives the data on 14-3-3  as a predictor of the 
2 surrogate end points of progressive disease (incident CIN 1+ 
and CIN 2+). The 3-tier grading of 14-3-3  expression was 
practically identical in the baseline biopsy specimens that sub-
sequently progressed to incident CIN1+, with no significant 
difference. Longitudinal performance indicators did not pro-
vide any useful values, with an AUC of 0.503. The same was 
true with 14-3-3  as a predictor of incident CIN 2+ (AUC, 
0.472). However, the negative predictive value approached 
90%, implying that negative-weak 14-3-3  expression pre-
cludes progression to CIN 2+ with high accuracy (95% CI, 
75.8%-97.1%). Times to progression to CIN 1+ or CIN 2+ 
were identical in different categories of 14-3-3  expression, 
with no significant differences (data not shown).
Discussion
Recent studies implied that the role of 14-3-3  in cell 
cycle control is more complex than previously anticipated. 
In addition to controlling the G2/M checkpoint, 14-3-3  also 
seems to control the G1/S checkpoint.12,14,22 In both cases, 
the effects are mediated by complex binding of 14-3-3  with 
a multitude of cellular proteins.12 In controlling the G2/M 
checkpoint, the association with 14-3-3 proteins requires a 
specific phosphorylation of the protein ligand, and 14-3-3 
binding may lead to cytoplasmic sequestration of the protein 
❚Table 3❚
Expression of Stratifin as Predictor of Different Outcomes of HR-HPV Infection*
Stratifin Expression  
End Point Negative-Normal Expression Moderate Up-Regulation Strong Up-Regulation
Incident HR HPV†   
   Yes (n = 1) 0 (0) 0 (0) 1 (100)
   No (n = 55) 24 (44) 19 (35) 12 (22)
HR HPV cleared‡   
   Yes (n = 14) 5 (36) 6 (43) 3 (21)
   No (n = 42) 19 (45) 13 (31) 10 (24)
HR HPV persistence§   
   Yes (n = 11) 2 (18) 5 (45) 4 (36)
   No (n = 45) 22 (49) 14 (31) 9 (20)
AUC, area under the receiver operating characteristic curve; CI, confidence interval; HPV, human papillomavirus; HR, high risk; M-S/N-W, moderate to strong vs negative to 
weak (normal); NPV, negative predictive value; PPV, positive predictive value.
* Data are given as number (percentage).
† P = .235 (Fisher exact test); P = .235 for linear trend. Longitudinal performance indicators of dichotomous (M-S/N-W) stratifin were as follows (95% CI in parentheses):
sensitivity, 100.0% (2.5-100); specificity, 43.6% (65.0-88.2); PPV, 3.1% (0.1-16.2); NPV, 100.0% (85.8-100); AUC, 0.718 (0.000-1.000).
‡ P = .726 (Fisher exact test); P = .846 for linear trend. Longitudinal performance indicators of dichotomous (M-S/N-W) stratifin were as follows (95% CI in parentheses):
sensitivity, 64.3% (35.1-87.2); specificity, 45.2% (29.8-61.3); PPV, 28.1% (13.7-46.7); NPV, 79.2% (57.8-92.9); AUC, 0.548 (0.397-0.698).
§ P = .175 (Fisher exact test); P = .095 for linear trend. Longitudinal performance indicators of dichotomous (M-S/N-W) stratifin were as follows (95% CI in parentheses):
sensitivity, 81.8% (48.2-97.7); specificity, 48.9% (33.7-64.2); PPV, 28.1% (13.7-46.7); NPV, 91.7% (73.0-99.0); AUC, 0.654 (0.513-0.794).
❚Table 4❚
Expression of Stratifin as a Predictor of the Two Surrogate End Points of Disease Progression*
Stratifin Expression  
End Point Negative-Normal Expression Moderate  Up-Regulation Strong  Up-Regulation
Incident CIN 1+†   
   Yes (n = 18) 7 (39) 4 (22) 7 (39)
   No (n = 81) 32 (40) 26 (32) 23 (28)
Incident CIN 2+‡   
   Yes (n = 9) 4 (44) 1 (11) 4 (44)
   No (n = 90) 35 (39) 29 (32) 26 (29)
AUC, area under the receiver operating characteristic curve; CI, confidence interval; CIN, cervical intraepithelial neoplasia; M-S/N-W, moderate to strong vs negative to weak 
(normal); NPV, negative predictive value; PPV, positive predictive value.
* Data are given as number (percentage).
† P = .643 (Fisher exact test); P = .641 for linear trend. Longitudinal performance indicators of dichotomous (M-S/N-W) stratifin were as follows (95% CI in parentheses):
sensitivity, 61.1% (35.7-82.7); specificity, 39.5% (28.8-51.0); PPV, 18.3% (9.5-30.4); NPV, 82.1% (66.5-92.5); AUC, 0.503 (0.375-0.631).
‡ P = .376 (Fisher exact test); P = .838 for linear trend. Longitudinal performance indicators of dichotomous (M-S/N-W) stratifin were as follows (95% CI in parentheses):








inho user on 16 O
ctober 2020
238     Am J Clin Pathol  2010;133:232-240
238     DOI: 10.1309/AJCP49DOITYDCTQJ    
© American Society for Clinical Pathology
Syrjänen et al / 14-3-3  (Stratifin) in Cervical HPV Lesions
the data of Sano et al,25 describing ubiquitous expression of 
14-3-3  in CIN and CC lesions, with increasing intensity 
among high-grade CIN and CC. In our series, some 14% of 
the CIN3 and 24% of CIN2 lesions still retained only weak 
expression, equivalent to normal epithelium. This obvious 
major up-regulation (from 47.6% to 72.2%) on transition from 
CIN 2 to CIN 3 is most feasibly explained by the fact that 
practically all CIN 3 lesions contain HR HPV DNA, imply-
ing an intimate association between 14-3-3  and HR HPV. 
This is in alignment with the recent observations on oral and 
vulvar cancer (and precursors) in which 14-3-3  was silenced 
typically in HPV– lesions only, not in HPV+ lesions.23,24
However, in CC and CIN, this association was not perfect, but 
14-3-3  was inactivated by promoter methylation also among 
a few HR-HPV+ lesions, implying that these 2 events are not 
mutually exclusive.25
The present data (Table 2) indicate that up-regulation of 
14-3-3  was closely associated with HR-HPV detection (P =
.008; P = .002 for linear trend). It is interesting that expression 
of 14-3-3  was also linearly related to the semiquantitative 
(HC2) viral load of HR HPV (P = .003), which increased in 
parallel with the increasing intensity of 14-3-3  expression, 
being almost 3 times higher among the lesions with intense 
overexpression of 14-3-3  as compared with the reference 
category (Table 2). However, unlike some other markers 
recently analyzed (p16INK4a, survivin, and hTERT),32 14-3-3
was not a useful marker of HR HPV (AUC, 0.608).
It is tempting to speculate that the presence of HR HPV 
is the reason why 14-3-3  is not inactivated in CIN and CC 
lesions, in contrast with practically all non-HPV–related car-
cinomas studied so far.14,22 This view is also consistent with 
the data on oral and vulvar cancers,23,24 in which 14-3-3
inactivation was a frequent phenomenon. In contrast with 
CIN and CC, only a minority of these lesions are associated 
with HR HPV, which would feasibly explain this difference. 
Noteworthy in all these studies,23-25 however, was the fact that 
14-3-3  inactivation by promoter methylation also occurred 
in a small proportion of HR-HPV+ lesions, indicating that 
these are not mutually exclusive. The observed weak expres-
sion in 22.5% of the HR-HPV+ lesions in our series could be 
consistent with this.
Considering the well-established tumor suppressive func-
tion of 14-3-3 ,12,14,15,19-22 one would expect that its abun-
dant expression should have some favorable impact on the 
outcome of HR-HPV infections or the progression to CIN. In 
the present study, we were unable to provide any confirma-
tory data to support either of these concepts. Thus, incident 
HR-HPV infections, virus clearance, or HR-HPV persistence 
did not show any direct association with 14-3-3  expression 
(Table 3), and longitudinal predictive indicators were not 
useful in predicting the 3 viral outcomes. Similarly, there 
was practically no difference in 14-3-3  expression patterns 
ligand. Indeed, the 14-3-3  gene is induced by p53, and its 
product inhibits G2/M progression by cytoplasmic sequestra-
tion of the CDC2-cyclin B complexes.12
To increase the complexity, 14-3-3 proteins are also 
involved in the regulation of G1/S-phase transition by several 
mechanisms.12 They bind to and negatively regulate CDC25 
phosphatases, which are involved in regulating the CDK 
complexes critical for G1/S-transition. Furthermore, a direct 
association of 14-3-3  with the G1-specific kinases CDK2 
and CDK4 is most likely mediated by a cyclin-CDK2 bind-
ing motif, which 14-3-3  seems to share with several other 
cell cycle regulators, including p107, p130, p21Cip1, p27Kip1,
and p57Kip2.12 It is important to note that 14-3-3 proteins may 
also directly interact with the CDK inhibitor p27Kip1, which 
mediates G1 arrest by inhibiting cyclin E–CDK2 complexes.12
In addition, 14-3-3 proteins have been implicated in the tran-
scriptional regulation of CDK inhibitors as they modulate the 
transcription factors p53, FOXO, and MIZ1.12
Considering the known complexity of the mechanisms 
whereby HR-HPV types regulate the cell cycle and other key 
cellular functions,1-3,7-9,11 there is little doubt that multiple 
potential sites of interaction between 14-3-3 proteins and 
HR-HPV oncoproteins E6 and E7 could exist. Until now, 
only 3 studies have analyzed expression of 14-3-3  and/or 
genetic and epigenetic changes in the gene in HPV-associated 
cancers (oral, vulvar, cervical).23-25 In oral and vulvar cancer 
(and their precursors) but not in CC and CIN, coincident 
loss of expression of 14-3-3  and p16INK4a was commonly 
detected, particularly in HPV– lesions.23-25 In contrast, CC 
and CIN ubiquitously expressed 14-3-3 , and concomitant 
inactivation of 14-3-3  and p16 was never detected.25 This 
leaves room for speculations that oral, vulvar, and cervical 
cancer might differ in details of how HR HPV1-3,7-9,11 and 
14-3-3 12,14,15,19-22 interfere with the normal cell functions 
and, particularly, how these two might interact.
In fact, several mechanisms could explain this detected 
up-regulation of 14-3-3  in CC and CIN.25 Expression of 
14-3-3  is up-regulated directly by interaction with HR HPV, 
or the presence of HR HPV is just incompatible with the 
epigenetic silencing of 14-3-3 . Is this up-regulated 14-3-3
impaired (inhibited) in its function (by HR HPV) to enable 
normal control of the cell cycle checkpoints? If still function-
al, there must be a mechanism whereby HR HPV can bypass 
these two 14-3-3 –controlled cell cycle checkpoints. Under 
any of these circumstances, one could expect to see some dif-
ferences in the 14-3-3  expression as related to the following: 
(1) the grade of CIN, (2) HR-HPV detection, (3) the outcome 
of these HR-HPV infections, and (4) development of incident 
CIN 1+ and CIN 2+, all examined in the present study.
Using the normal squamous epithelium as a reference, 
the expression of 14-3-3  seems to increase in parallel with 
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with CIN 2/3 and HR-HPV infection, feasibly explained by 
the actions of E7 oncoprotein reverting the p21Cip1-mediated 
control of PCNA.35 It is tempting to speculate that something 
analogous might take place that explains this similar associa-
tion of PCNA35 and 14-3-3  overexpression with high-grade 
CIN and HR-HPV detection.
Unlike in most other human cancers, 14-3-3  (stratifin) 
in CC and CIN is rarely inactivated, but, in contrast, seems 
to be overexpressed in high-grade lesions associated with 
HR-HPV infection. Thus, rather than being inactivated (by 
epigenetic promoter methylation), 14-3-3  is expressed in 
CIN and CC, but, evidently, its normal control functions on 
the G1/S and G2/M checkpoints are being bypassed by HR 
HPV using some as yet unknown molecular mechanisms.
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